-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Do we still need so many medical representatives for the normalization of volume procurement?
1.
1.
According to US media reports including the Denver Business Journal, Novartis closed its Longmont, Colorado plant after acquiring it from AstraZeneca in 2019.
Personnel changes caused by poor product sales are common internationally.
To some extent, few foreign companies can "fully embrace" large-volume procurement.
Senior medical representative Joe said to Cyberland: The current response strategy of foreign companies to centralized procurement is to abolish and reduce the size of the team that may purchase products in the future, outsourcing products that are not well done, merging between mature products, and focusing on the layout of innovative drugs.
"In fact, the innovative drugs of various foreign companies are already in the early stages of high-speed listing.
2.
2.
He believes: The products of foreign pharmaceutical companies are mainly adjusted in three steps.
The second is mature products, which are products that the company has sold well before, such as some varieties of high blood pressure and diabetes-these varieties have patient awareness, and after years of building a network of experts, patients and expert brands Awareness is relatively high.
Often when patients are treated, they not only consider the price of the product, but also consider whether the product can solve their own disease and solve their own problems.
Zhao Jiazhen added: The third strategy of foreign pharmaceutical companies is to vigorously develop new specialty drugs and innovative drugs.
of course.
Therefore, since it is said to be new specialty drugs or innovative drugs, the prices of these drugs may inevitably be very high.
The three strategic adjustments of foreign companies will inevitably bring about changes in the personnel of medical representatives, which ushered in an eternal topic: Will there still be so many medical representatives in the future?
Nowadays, the hierarchical approach of national centralized procurement + provincial/interprovincial + municipal volume procurement has become the consensus of the industry.
Joe believes that in the future, medical representatives will need more skills.
It is a bit like the Roche ecosystem.
The marketing department, medical department, and sales department are required to be done by medical representatives.
In short, it means more than one job.
Therefore, it is inevitable to reduce the number of people.